Journal of Biological Chemistry · 2019 · 18 citations · 34 references
Life SciencesMolecular BiologyNeuroscienceGenome EditingMolecular NeuroscienceNeurodegenerationAlzheimer DiseaseCrispr-cas SystemsNeurodegenerative DiseasesNeurodegenerative DisordersAmyloid Beta PeptidesAmyloid InhibitionCrispr-cas9 Genome EditingGamma Secretase InhibitionKnockout Mouse ModelsPresenilin MutationsTransgenic Cell LinesTransgenic Mouse Models
Presenilins 1 and 2 (PS1 and 2) are the catalytic subunits of γ-secretase, a multiprotein protease that cleaves amyloid protein precursor and other type I transmembrane proteins. Previous studies with mouse models or cells have indicated differences in PS1 and PS2 functions. We have recently reported that clinical γ-secretase inhibitors (GSIs), initially developed to manage Alzheimer's disease and now being considered for other therapeutic interventions, are both pharmacologically and functionally distinct. Here, using CRISPR/Cas9-based gene editing, we established human HEK 293T cell lines in which endogenous PS1, PS2, or both have been knocked out. Using these knockout lines to examine differences in PS1- and PS2-mediated cleavage events, we confirmed that PS2 generates more intracellular β-amyloid than does PS1. Moreover, we observed subtle differences in PS1- and PS2-mediated cleavages of select substrates. In exploring the question of whether differences in activity among clinical GSIs could be attributed to differential inhibition of PS1 or PS2, we noted that select GSIs inhibit PS1 and PS2 activities on specific substrates with slightly different potencies. We also found that endoproteolysis of select PS1 FAD-linked variants in human cells is more efficient than what has been previously reported for mouse cell lines. Overall, these results obtained with HEK293T cells suggest that selective PS1 or PS2 inhibition by a given GSI does not explain the previously observed differences in functional and pharmacological properties among various GSIs.
34
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran, Patrick D. Hsu, Jason Wright et al. · Nature Protocols · 2013 · 11.7K citations · Full text
Analysis of protein-coding genetic variation in 60,706 humans
Monkol Lek, Konrad J. Karczewski, Eric Vallabh Minikel et al. · Nature · 2016 · 10.3K citations · Full text
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
Bart De Strooper, Paul Säftig, Katleen Craessaerts et al. · Nature · 1998 · 1.8K citations
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody, Rema Raman, Martin R. Farlow et al. · New England Journal of Medicine · 2013 · 1.2K citations
Endoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Gopal Thinakaran, David Borchelt, Michael K. Lee et al. · Neuron · 1996 · 1K citations · Full text